NASDAQ:CAPS Capstone Therapeutics (CAPS) Stock Price, News & Analysis $0.12 -0.01 (-6.83%) Closing price 04:00 PM EasternExtended Trading$0.12 0.00 (-0.16%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Capstone Therapeutics Stock (NASDAQ:CAPS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Capstone Therapeutics alerts:Sign Up Key Stats Today's Range$0.12▼$0.1450-Day Range$0.12▼$0.3252-Week Range$0.12▼$1.36Volume908,822 shsAverage Volume12.70 million shsMarket Capitalization$2.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics. Its research activities centered on modified peptides intended to address metabolic and other medical conditions. The company’s best-known development program involved AOD9604, a synthetic peptide derived from a fragment of human growth hormone. AOD9604 was investigated primarily for its potential use in weight management and metabolic disorders, although development and commercialization status may have changed over time. Capstone Therapeutics was based in the United States and operated as a development-stage biotechnology company. Publicly available information about its current operations, leadership, geographic reach and product portfolio is limited, and the company’s historical trading information may not reflect an active Nasdaq listing.AI Generated. May Contain Errors. Read More Capstone Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreCAPS MarketRank™: 0.37402871065 of 5 starsCapstone Therapeutics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCapstone Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCapstone Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Capstone Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCapstone Therapeutics has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Capstone Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.21% of the float of Capstone Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapstone Therapeutics has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Capstone Therapeutics has recently increased by 2,091.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapstone Therapeutics does not currently pay a dividend.Dividend GrowthCapstone Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.91 News SentimentCapstone Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Capstone Therapeutics this week, compared to 3 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Capstone Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders39.29% of the stock of Capstone Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.55% of the stock of Capstone Therapeutics is held by institutions.Read more about Capstone Therapeutics' insider trading history. Receive CAPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capstone Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPS Stock News HeadlinesLocaliza Rent a Car (OTCMKTS:LZRFY) versus Capstone Therapeutics (NASDAQ:CAPS) Head-To-Head ReviewOctober 12 at 7:44 AM | americanbankingnews.comCapstone reports 7.6% revenue growth with gross profit aheadOctober 4, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 13 at 1:00 AM | Stansberry Research (Ad)Capstone Publishes Investor FAQ: 75% of Convertible Note Principal Retired, Approximately $1.72 Million RemainingAugust 26, 2026 | businesswire.comCapstone Reports Q2 2026 Results: Revenue Up 67%, Gross Profit Up 92%, Stone Business Adjusted EBITDA Turns Positive as GuidedAugust 12, 2026 | businesswire.comCapstone Receives Additional 180-Day Nasdaq Compliance PeriodJuly 9, 2026 | businesswire.comCapstone Extends Credit Facilities with Beacon Bank and Stream Finance on Identical TermsJune 22, 2026 | businesswire.comCapstone Expands D.R. Horton Relationship to 19 Communities and Wins All of a Leading National Homebuilder's Regional Stone WorkJune 1, 2026 | businesswire.comSee More Headlines CAPS Stock Analysis - Frequently Asked Questions How have CAPS shares performed this year? Capstone Therapeutics' stock was trading at $0.7279 at the beginning of 2026. Since then, CAPS stock has decreased by 82.9% and is now trading at $0.1242. How were Capstone Therapeutics' earnings last quarter? Capstone Therapeutics Corp. (NASDAQ:CAPS) released its quarterly earnings data on Tuesday, November, 18th. The company reported ($0.35) EPS for the quarter. The company earned $13.65 million during the quarter. Capstone Therapeutics had a negative net margin of 36.51% and a negative trailing twelve-month return on equity of 144.43%. Read the conference call transcript. When did Capstone Therapeutics IPO? Capstone Therapeutics (CAPS) raised $5 million in an initial public offering (IPO) on Thursday, March 6th 2025. The company issued 1,250,000 shares at $4.00 per share. How do I buy shares of Capstone Therapeutics? Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/18/2025Today10/13/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Trading Companies & Distributors Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:CAPS Previous SymbolOTCMKTS:CAPS CIK887151 Webwww.capstoneholdingcorp.com Phone(708) 371-0660Fax602-286-5300Employees93Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.23 million Net Margins-36.51% Pretax Margin-24.64% Return on Equity-144.43% Return on Assets-40.48% Debt Debt-to-Equity Ratio0.69 Current Ratio0.99 Quick Ratio0.39 Sales & Book Value Annual Sales$48.11 million Price / Sales0.05 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book0.09Miscellaneous Outstanding Shares20,580,000Free Float12,494,000Market Cap$2.56 million OptionableN/A Beta-1.50 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CAPS) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
